Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief ...
Progress significantly enhances the strategic attractiveness of ATP-R13 as a broadly applicable, disease-modifying therapy across multiple allergic indications Geneva (Switzerland), January 20, 2026 – ...
Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthma Positive opinion from the European Patent Office strengthens patent protection of ATP-R13 Progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results